Magnitude of benefit of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for malignant tumor: A meta-analysis

被引：18
作者：
Gu, Lihu [1 ]
Du, Nannan [2 ]
Jin, Qiong [3 ]
Li, Shengnan [2 ]
Xie, Laidi [4 ]
Mo, Jiahang [2 ]
Shen, Zefeng [2 ]
Mao, Danyi [5 ]
Ji, Jia [2 ]
Khadaroo, Parikshit Asutosh [6 ]
Chen, Bangsheng [3 ]
机构：
[1] Univ Chinese Acad Sci, HwaMei Hosp, Dept Gen Surg, Ningbo, Zhejiang, Peoples R China
[2] Zhejiang Chinese Med Univ, Clin Med Coll 2, Hangzhou, Zhejiang, Peoples R China
[3] Second Hosp Yinzhou, Emergency Med Ctr, 998 North Qianhe Rd, Ningbo 315100, Zhejiang, Peoples R China
[4] Zhejiang Univ, Coll Obstet & Gynecol, Sch Med, Hangzhou, Peoples R China
[5] Zhejiang Chinese Med Univ, Basic Med Coll, Hangzhou, Zhejiang, Peoples R China
[6] Monash Univ, Sch Med Nursing & Hlth Sci, Melbourne, Vic, Australia
来源：
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2020年 / 147卷
关键词：
PARP inhibitor; Survival; BRCA1/2; Adverse events; Evaluation of solid tumors; SENSITIVE OVARIAN-CANCER; DOUBLE-BLIND; POLY(ADP-RIBOSE) POLYMERASE; MAINTENANCE THERAPY; DOSE-ESCALATION; OPEN-LABEL; PHASE-II; OLAPARIB; RECURRENT; EFFICACY;
D O I：
10.1016/j.critrevonc.2020.102888
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: The purpose of this study was to analyze the efficacy of PARP inhibitor on solid tumors. Methods: For this study, the following databases were searched for articles published from its inception until July 2019: PubMed, Web of Science, EBSCO, and Cochrane library, of which the main conclusion was the overall survival (OS) and progression-free survival (PFS). Results: We conducted a meta-analysis and the results showed that PARP inhibitor increased the patients' PFS (HR: 0.51, p < 0.001), PFS with BRCA1/2 mutations (HR: 0.32, p < 0.001), OS (HR: 0.74, p < 0.001), OS with BRCA1/2 mutations (HR: 0.78, p = 0.03), complete response (CR) (RR: 1.89, p = 0.10), partial response (PR) (RR: 1.34, p = 0.01), overall response rate (ORR) (RR: 1.42, p = 0.001) respectively. The main adverse events (AEs) observed were decreased appetite. Conclusions: PARP inhibitors may prolong survival. PARP inhibitors were more favorable for BRCA1/2 mutations in ovarian cancer patients. Additionally, the overall safety factor was controllable.
引用
收藏
页数：8
相关论文
共 35 条
[1]   Understanding the mismatch between the demands of risk assessment and practice of scientists - The case of Deca-BDE [J].
Alcock, Ruth E. ;
MacGillivray, Brian H. ;
Busby, Jerry S. .
ENVIRONMENT INTERNATIONAL, 2011, 37 (01) :216-225
[2]   The PARP superfamily [J].
Amé, JC ;
Spenlehauer, C ;
de Murcia, G .
BIOESSAYS, 2004, 26 (08) :882-893
[3]   Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer [J].
Bang, Yung-Jue ;
Im, Seock-Ah ;
Lee, Keun-Wook ;
Cho, Jae Yong ;
Song, Eun-Kee ;
Lee, Kyung Hee ;
Kim, Yeul Hong ;
Park, Joon Oh ;
Chun, Hoo Geun ;
Zang, Dae Young ;
Fielding, Anitra ;
Rowbottom, Jacqui ;
Hodgson, Darren ;
O'Connor, Mark J. ;
Yin, Xiaolu ;
Kim, Woo Ho .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (33) :3858-+
[4]   Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data [J].
Chartron, Elodie ;
Theillet, Charles ;
Guiu, Severine ;
Jacot, William .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 133 :58-73
[5]   Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial [J].
Clarke, Noel ;
Wiechno, Pawel ;
Alekseev, Boris ;
Sala, Nuria ;
Jones, Robert ;
Kocak, Ivo ;
Chiuri, Vincenzo Emanuele ;
Jassem, Jacek ;
Flechon, Aude ;
Redfern, Charles ;
Goessl, Carsten ;
Burgents, Joseph ;
Kozarski, Robert ;
Hodgson, Darren ;
Learoyd, Maria ;
Saad, Fred .
LANCET ONCOLOGY, 2018, 19 (07) :975-986
[6]   Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [J].
Coleman, Robert L. ;
Oza, Amit M. ;
Lorusso, Domenico ;
Aghajanian, Carol ;
Oaknin, Ana ;
Dean, Andrew ;
Colombo, Nicoletta ;
Weberpals, Johanne, I ;
Clamp, Andrew ;
Scambia, Giovanni ;
Leary, Alexandra ;
Holloway, Robert W. ;
Amenedo Gancedo, Margarita ;
Fong, Peter C. ;
Goh, Jeffrey C. ;
O'Malley, David M. ;
Armstrong, Deborah K. ;
Garcia-Donas, Jesus ;
Swisher, Elizabeth M. ;
Floquet, Anne ;
Konecny, Gottfried E. ;
McNeish, lain A. ;
Scott, Clare L. ;
Cameron, Terri ;
Maloney, Lara ;
Isaacson, Jeff ;
Goble, Sandra ;
Grace, Caroline ;
Harding, Thomas C. ;
Raponi, Mitch ;
Sun, James ;
Lin, Kevin K. ;
Giordano, Heidi ;
Ledermann, Jonathan A. .
LANCET, 2017, 390 (10106) :1949-1961
[7]  
Del Campo J.M., 2019, J CLIN ONCOL JCO
[8]   Comparison of Quality of Life and Nutritional Status of Between Roux-en-Y and Billroth-I Reconstruction After Distal Gastrectomy: A Systematic Review and Meta-Analysis [J].
Du, Nannan ;
Chen, Manman ;
Shen, Zefeng ;
Li, Shengnan ;
Chen, Ping ;
Khadaroo, Parishit A. ;
Mao, Danyi ;
Gu, Lihu .
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2020, 72 (05) :849-857
[9]   Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers. [J].
Fong, Peter C. ;
Boss, David S. ;
Yap, Timothy A. ;
Tutt, Andrew ;
Wu, Peijun ;
Mergui-Roelvink, Marja ;
Mortimer, Peter ;
Swaisland, Helen ;
Lau, Alan ;
O'Connor, Mark J. ;
Ashworth, Alan ;
Carmichael, James ;
Kaye, Stan B. ;
Schellens, Jan H. M. ;
de Bono, Johann S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (02) :123-134
[10]   Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer [J].
Golan, Talia ;
Hammel, Pascal ;
Reni, Michele ;
Van Cutsem, Eric ;
Macarulla, Teresa ;
Hall, Michael J. ;
Park, Joon-Oh ;
Hochhauser, Daniel ;
Arnold, Dirk ;
Oh, Do-Youn ;
Reinacher-Schick, Anke ;
Tortora, Giampaolo ;
Alguel, Hana ;
O'Reilly, Eileen M. ;
McGuinness, David ;
Cui, Karen Y. ;
Schlienger, Katia ;
Locker, Gershon Y. ;
Kindler, Hedy L. .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (04) :317-327
1234